Questiomycin A

Questiomycin A (Phx-3) is a GRP78 (cytoprotective endoplasmic reticulum chaperone) degrader and enhances the anticancer activity of Sorafenib. Questiomycin A is also an antimicrobial/antibiotic that can be obtained from the metabolite of Pseudomonas chlororaphis HT66. Questiomycin A can be used in research on biological control of cancer and plant diseases[1][2].

Product Specifications

CAS Number

[1916-59-2]

Product Name Alternative

Phx-3

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Antibiotic; Bacterial; HSP

Type

Natural Products

Related Pathways

Anti-infection; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/questiomycin-a.html

Purity

99.19

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

O=C1C(N)=CC2=NC3=C(C=CC=C3)OC2=C1

Molecular Formula

C12H8N2O2

Molecular Weight

212.20

Precautions

H315, H319, H335

References & Citations

[1]Machihara K, et al. Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78. Biochem Biophys Res Commun. 2017 Oct 7;492 (1) :33-40.|[2]Guo S, et al. Production of Antibacterial Questiomycin A in Metabolically Engineered Pseudomonas chlororaphis HT66. J Agric Food Chem. 2022 Jun 29;70 (25) :7742-7750.